TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23238388

Group type: EXPERIMENTAL
Intervention: Topical vitamin K1 cream
Number of subjects: 101

Group type: COMPARATOR
Intervention: Historical control (no vitamin K1 cream)
Number of subjects: 101
Study: 21497108

Group type: EXPERIMENTAL
Intervention: Left single-lung transplantation (L-SLTx)
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Right single-lung transplantation (R-SLTx)
Number of subjects: 142

Group type: COMPARATOR
Intervention: Both L-SLTx and R-SLTx
Number of subjects: 142
Study: 18279044

Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy
Number of subjects: 0
Study: 15339999

Group type: EXPERIMENTAL
Intervention: Intravenous ascorbic acid (IVAA) 2000 mg
Number of subjects: 36

Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 36
Study: 11228382

Group type: EXPERIMENTAL
Intervention: ALM+BCG
Number of subjects: 3

Group type: COMPARATOR
Intervention: BCG
Number of subjects: 3

Group type: COMPARATOR
Intervention: Vaccine diluent
Number of subjects: 3
Study: 9608601

Group type: EXPERIMENTAL
Intervention: 0.25 mg of triazolam
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 8032035

Group type: EXPERIMENTAL
Intervention: Advice and targets for changing lifestyle
Number of subjects: 297

Group type: COMPARATOR
Intervention: Results only (Control)
Number of subjects: 297
Study: 2531676

Group type: EXPERIMENTAL
Intervention: Smoking Prevention Program (based on the Waterloo Smoking Program)
Number of subjects: 1013

Group type: COMPARATOR
Intervention: Cardiovascular Risk Prevention Program (control group, based on an ad hoc program by the USL)
Number of subjects: 1013
Study: 1092210

Group type: EXPERIMENTAL
Intervention: Alupent Syrup (metaproterenol sulfate)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 31438954

Group type: EXPERIMENTAL
Intervention: Acupuncture treatment
Number of subjects: 44818

Group type: COMPARATOR
Intervention: Physicians' reporting
Number of subjects: 44818

Group type: EXPERIMENTAL
Intervention: Cohen's kappa for agreement
Number of subjects: 44818
Study: 28463756

Group type: EXPERIMENTAL
Intervention: FOLFIRI plus cetuximab
Number of subjects: 236

Group type: COMPARATOR
Intervention: FOLFIRI plus bevacizumab
Number of subjects: 236
Study: 26109992

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study: 23150709

Group type: EXPERIMENTAL
Intervention: Chemotherapy including bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (6-8 cycles)
Number of subjects: 1323
Study: 22066973

Group type: EXPERIMENTAL
Intervention: 0.125% ropivacaine plus tramadol 5 mg/mL
Number of subjects: 61

Group type: COMPARATOR
Intervention: 0.125% ropivacaine plus fentanyl 3 ug/mL
Number of subjects: 61
Study: 19299400

Group type: EXPERIMENTAL
Intervention: Retrofitting insulation
Number of subjects: 1350
Study: 16944096

Group type: EXPERIMENTAL
Intervention: 6-month aerobic exercise programme (30 min, three times a week, 70-80% of maximal heart rate)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Standard care control group
Number of subjects: 59
Study: 15614660

Group type: EXPERIMENTAL
Intervention: 12-week physical activity program
Number of subjects: 177

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 177
Study: 11524468

Group type: EXPERIMENTAL
Intervention: Donepezil 10 mg/day after initial 5 mg/day for 28 days
Number of subjects: 290

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 290
Study: 9252712

Group type: EXPERIMENTAL
Intervention: Maintenance endocrine therapy (MET)
Number of subjects: 207

Group type: COMPARATOR
Intervention: Epirubicin (120 mg/sqm) +/− lonidamine (600 mg/daily)
Number of subjects: 207
Study: 8325946

Group type: EXPERIMENTAL
Intervention: Thyroxine (T4) 180 micrograms daily for 3 weeks, then 360 micrograms daily for 3 weeks
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: 3,5,3'-triiodothyroacetic acid (Triac) 1700 micrograms daily for 3 weeks, then 3400 micrograms daily for 3 weeks
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 14
Study: 3551970

Group type: EXPERIMENTAL
Intervention: Midazolam 15 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Midazolam 30 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Midazolam (both doses)
Number of subjects: 0
Study: 29998439

Group type: EXPERIMENTAL
Intervention: Ropren (polyprenol-containing drug)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 0
Study: 27085126

Group type: EXPERIMENTAL
Intervention: Guided skiing for 12 weeks (n=22); average heart rate 72.7% of maximum
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Guided skiing for 12 weeks (n=22)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group (n=20)
Number of subjects: 42
Study: 24839206

Group type: EXPERIMENTAL
Intervention: Rilonacept (loading dose 4.4 mg/kg followed by 2.2 mg/kg weekly, subcutaneously)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Rilonacept
Number of subjects: 71

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71

Group type: COMPARATOR
Intervention: Rilonacept and Placebo
Number of subjects: 71
Study: 21929831

Group type: EXPERIMENTAL
Intervention: Face to face cognitive behaviour therapy (CBT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Telephone cognitive behaviour therapy (CBT)
Number of subjects: 0
Study: 20484618

Group type: EXPERIMENTAL
Intervention: Oritavancin 800 mg intravenously
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Oritavancin 200 mg intravenously
Number of subjects: 240

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 240

Group type: COMPARATOR
Intervention: Moxifloxacin 400 mg orally
Number of subjects: 240
Study: 18359186

Group type: EXPERIMENTAL
Intervention: Mindfulness Based Stress Reduction (MBSR) program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-MBSR (control group)
Number of subjects: 0
Study: 16002807

Group type: EXPERIMENTAL
Intervention: 15 mg Zn supplementation
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: 30 mg Zn supplementation
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo (0 mg Zn)
Number of subjects: 48
Study: 12084809

Group type: EXPERIMENTAL
Intervention: Transdermal testosterone (2-2.5 mg patches/d)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Placebo patches
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Transdermal testosterone
Number of subjects: 67
Study: 10214570

Group type: EXPERIMENTAL
Intervention: ADCON-L
Number of subjects: 298

Group type: COMPARATOR
Intervention: Control (no ADCON-L)
Number of subjects: 298
Study: 8592310

Group type: EXPERIMENTAL
Intervention: Diaphragm with spermicide
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Diaphragm only
Number of subjects: 216

Group type: COMPARATOR
Intervention: Spermicide only (control group)
Number of subjects: 216
Study: 2775143

Group type: EXPERIMENTAL
Intervention: Cognitive therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Additional treatment based on the depression model
Number of subjects: 0
Study: 795498

Group type: EXPERIMENTAL
Intervention: Intramuscular dexamethasone combined with intravenous low‐molecular‐weight dextran (dextran 40)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 31628894

Group type: EXPERIMENTAL
Intervention: Spino-cerebellar tDCS (anodal spinal tDCS with cathodal cerebellar tDCS)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 37
Study: 28559399

Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 39763

Group type: EXPERIMENTAL
Intervention: Lisinopril
Number of subjects: 39763

Group type: EXPERIMENTAL
Intervention: Doxazosin
Number of subjects: 39763

Group type: EXPERIMENTAL
Intervention: Nonimmediate responders
Number of subjects: 39763

Group type: COMPARATOR
Intervention: Chlorthalidone
Number of subjects: 39763
Study: 25222091

Group type: EXPERIMENTAL
Intervention: Upright seated posture
Number of subjects: 74

Group type: COMPARATOR
Intervention: Slumped seated posture
Number of subjects: 74
Study: 23903527

Group type: EXPERIMENTAL
Intervention: Rugby League players
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 46
Study: 22165359

Group type: EXPERIMENTAL
Intervention: Pharmacist supplementary prescribing
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Pharmacist medication history only
Number of subjects: 360

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 360
Study: 19543909

Group type: EXPERIMENTAL
Intervention: SDEP
Number of subjects: 11

Group type: COMPARATOR
Intervention: CON
Number of subjects: 11
Study: 16937386

Group type: EXPERIMENTAL
Intervention: Family-based therapy (FBT)
Number of subjects: 0
Study: 15512838

Group type: EXPERIMENTAL
Intervention: Topical anesthetic (5g EMLA)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 10
Study: 10930969

Group type: EXPERIMENTAL
Intervention: MEMS system
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Self‐report scores (Morisky)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Tablet counts
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Blood concentration assays
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Nordothiepin:dothiepin ratio > or = 1.1
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Overall compliance
Number of subjects: 88
Study: 10812314

Group type: EXPERIMENTAL
Intervention: Therapeutic community program
Number of subjects: 1573

Group type: EXPERIMENTAL
Intervention: Chemical dependency program
Number of subjects: 1573
Study: 8857135

Group type: EXPERIMENTAL
Intervention: Hyoscine n‐butyl bromide 20 mg
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study: 1996746

Group type: EXPERIMENTAL
Intervention: Propofol 2 mg/kg for induction followed by 6 mg/kg/hour for maintenance
Number of subjects: 40

Group type: COMPARATOR
Intervention: Thiopentone 4 mg/kg with enflurane 1% for maintenance
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Propofol infusion
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both groups (Propofol and Thiopentone/Enflurane)
Number of subjects: 40
Study: 6374869

Group type: EXPERIMENTAL
Intervention: Proximal gastric vagotomy
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Truncal vagotomy
Number of subjects: 101

Group type: COMPARATOR
Intervention: Simple closure
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Basal and pentagastrin‐ and insulin‐stimulated acid outputs
Number of subjects: 101

Group type: COMPARATOR
Intervention: Simple closure of perforation
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Acid secretory data and serum gastrin levels
Number of subjects: 101
Study: 30358536

Group type: COMPARATOR
Intervention: AC regimen (doxorubicine 50 mg/m2, cyclophosphamide 500 mg/m2)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: AC+Arglabin regimen (Arglabin 370 mg/m2 within 7 days)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Arglabin as monotherapy
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: AC+Arglabin regimen
Number of subjects: 93

Group type: COMPARATOR
Intervention: AC regimen
Number of subjects: 93
Study: 26836161

Group type: EXPERIMENTAL
Intervention: Cognitive stimulation (CS) in Subgroup 1 (MMSE_s <26)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Cognitive stimulation (CS) in Subgroup 2 (MMSE_s ≥26)
Number of subjects: 2
Study: 24252311

Group type: EXPERIMENTAL
Intervention: SCT intervention
Number of subjects: 170

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 170
Study: 22901437

Group type: EXPERIMENTAL
Intervention: SMS reminders for medication adherence
Number of subjects: 254

Group type: COMPARATOR
Intervention: Control group (no SMS reminders)
Number of subjects: 254
Study: 19730998

Group type: EXPERIMENTAL
Intervention: Pop-up messages
Number of subjects: 251

Group type: EXPERIMENTAL
Intervention: Self-appraisal messages
Number of subjects: 251

Group type: COMPARATOR
Intervention: Static messages
Number of subjects: 251

Group type: COMPARATOR
Intervention: Control/blank messages
Number of subjects: 251
Study: 17643277

Group type: EXPERIMENTAL
Intervention: Indacaterol 200 microg
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Indacaterol 400 microg
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Indacaterol 600 microg
Number of subjects: 156

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Indacaterol (200-600 microg)
Number of subjects: 156
Study: 15863650

Group type: EXPERIMENTAL
Intervention: MSV-1 (five immunodominant antigens: TB10.4, ESAT-6, CFP-8, CFP-10, CFP-15)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MSV-2 (antigens: CFP-11, CFP-21, CFP-22.5, MPT-64, CFP-31)
Number of subjects: 0

Group type: COMPARATOR
Intervention: BCG (bacille Calmette-Guerin)
Number of subjects: 0
Study: 11981144

Group type: EXPERIMENTAL
Intervention: 36 microg intrathecal fentanyl
Number of subjects: 75

Group type: COMPARATOR
Intervention: 8 microg intrathecal sufentanil
Number of subjects: 75
Study: 9535147

Group type: EXPERIMENTAL
Intervention: 0.25 mg adrenocorticotropin 1‐24
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 7702050

Group type: EXPERIMENTAL
Intervention: Low-flux biocompatible polymethylmethacrylate membrane
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Low-flux complement-activating cuprophane membrane
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: High-flux biocompatible polysulfone membrane
Number of subjects: 8

Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 8
Study: 2719498

Group type: EXPERIMENTAL
Intervention: Magnesium (15 mmol/d)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study: 31830404

Group type: EXPERIMENTAL
Intervention: Yoga exercises (three weekly sessions including meditation, breathing control, and slow body movements)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 70
Study: 30567838

Group type: EXPERIMENTAL
Intervention: Watson's Human Caring Model nursing care provided at home for 8 weeks
Number of subjects: 158

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 158
Study: 26260878

Group type: EXPERIMENTAL
Intervention: Bobath-based trunk exercises
Number of subjects: 22

Group type: COMPARATOR
Intervention: Conventional exercises (control group)
Number of subjects: 22
Study: 24149088

Group type: EXPERIMENTAL
Intervention: HPV infection (any HPV)
Number of subjects: 2519

Group type: EXPERIMENTAL
Intervention: High-risk HPV infection
Number of subjects: 2519

Group type: EXPERIMENTAL
Intervention: Each additional HPV genotype infection
Number of subjects: 2519

Group type: EXPERIMENTAL
Intervention: Persistent HPV infection
Number of subjects: 2519

Group type: EXPERIMENTAL
Intervention: Recently cleared HPV infection
Number of subjects: 2519
Study: 22424859

Group type: EXPERIMENTAL
Intervention: Pregabalin 150 mg BID
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 19645217

Group type: EXPERIMENTAL
Intervention: Diclofenac formulations with sample size N = 12
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Diclofenac formulations with sample size N = 24
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: All trials for all pharmacokinetic parameters
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Power of 0.8
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: All trials
Number of subjects: 12
Study: 18717761

Group type: EXPERIMENTAL
Intervention: Branched-chain amino acid-enriched nutrient-mixture (AEN group)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Control group (no supplementation)
Number of subjects: 112
Study: 16210020

Group type: EXPERIMENTAL
Intervention: 1 micromol/L FF-MAS
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: 10 micromol/L FF-MAS
Number of subjects: 218

Group type: COMPARATOR
Intervention: 0.2% recombinant human albumin (vehicle control)
Number of subjects: 218

Group type: COMPARATOR
Intervention: Medium alone (control)
Number of subjects: 218

Group type: COMPARATOR
Intervention: All groups (including controls)
Number of subjects: 218
Study: 11809164

Group type: EXPERIMENTAL
Intervention: Landmark-based segmentation method applied to MRI scans of patients with vascular dementia
Number of subjects: 20

Group type: COMPARATOR
Intervention: Landmark-based segmentation method applied to MRI scans of healthy elderly subjects
Number of subjects: 20
Study: 10511914

Group type: EXPERIMENTAL
Intervention: Modified method of in-vivo estimation of sound velocity in the lens during 2 to 3 seconds.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Customary method of IOL power calculation.
Number of subjects: 0
Study: 7854531

Group type: EXPERIMENTAL
Intervention: Duchenne muscular dystrophy (DMD) patients
Number of subjects: 19

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 19
Study: 1682177

Group type: EXPERIMENTAL
Intervention: Low dose acetyl salicylic acid (ASA) 75 mg/day for 10 days
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conventional therapy for 10 days
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Crossover to ASA after conventional therapy
Number of subjects: 20

Group type: COMPARATOR
Intervention: Crossover to conventional therapy after ASA
Number of subjects: 20
Study: 6291355

Group type: EXPERIMENTAL
Intervention: Pyrantel pamoate (Combantrin) at a dose of 20 mg/kg body weight for 1‐3 days
Number of subjects: 185

Group type: COMPARATOR
Intervention: Pyrantel pamoate (Combantrin)
Number of subjects: 185
Study: 31498389

Group type: EXPERIMENTAL
Intervention: Active tDCS
Number of subjects: 22

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 22
Study: 30453747

Group type: EXPERIMENTAL
Intervention: 20-minute mindful breathing
Number of subjects: 40

Group type: COMPARATOR
Intervention: 20-minute supportive listening
Number of subjects: 40
Study: 28081888

Group type: EXPERIMENTAL
Intervention: Computerized sexual health survey with decision support for STI testing
Number of subjects: 728

Group type: COMPARATOR
Intervention: Usual care without decision support
Number of subjects: 728

Group type: EXPERIMENTAL
Intervention: Computerized sexual health survey with decision support for STI testing among asymptomatic patients
Number of subjects: 728

Group type: COMPARATOR
Intervention: Usual care without decision support among asymptomatic patients
Number of subjects: 728
Study: 26467573

Group type: EXPERIMENTAL
Intervention: Personalized advice via the Internet based on current PA plus diet (Level 1, L1)
Number of subjects: 1607

Group type: EXPERIMENTAL
Intervention: Personalized advice via the Internet based on PA plus diet and phenotype (Level 2, L2)
Number of subjects: 1607

Group type: EXPERIMENTAL
Intervention: Personalized advice via the Internet based on PA plus diet, phenotype, and genotype (Level 3, L3)
Number of subjects: 1607

Group type: EXPERIMENTAL
Intervention: Advised to increase PA (all personalized groups)
Number of subjects: 1607

Group type: COMPARATOR
Intervention: Control group (nonpersonalized advice, Level 0, L0)
Number of subjects: 1607
Study: 23529173

Group type: EXPERIMENTAL
Intervention: lisinopril
Number of subjects: 33500

Group type: EXPERIMENTAL
Intervention: amlodipine
Number of subjects: 33500

Group type: COMPARATOR
Intervention: chlorthalidone
Number of subjects: 33500
Study: 21817186

Group type: EXPERIMENTAL
Intervention: nevirapine plus lopinavir/ritonavir (533/133 mg twice daily)
Number of subjects: 122

Group type: COMPARATOR
Intervention: zidovudine/lamivudine plus lopinavir/ritonavir (400/100 mg twice daily)
Number of subjects: 122
Study: 19927228

Group type: EXPERIMENTAL
Intervention: Existing treatment options for osteoporosis and fracture prevention, including potent antiresorptive and anabolic agents.
Number of subjects: 0
Study: 17689173

Group type: EXPERIMENTAL
Intervention: Carbohydrate drinks
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo drinks
Number of subjects: 37
Study: 15104769

Group type: EXPERIMENTAL
Intervention: Invasive approach (angiography before 48 hours)
Number of subjects: 1078

Group type: EXPERIMENTAL
Intervention: Invasive approach (angiography after 48 hours)
Number of subjects: 1078
Study: 11806392

Group type: EXPERIMENTAL
Intervention: Transpedicular grafting (TPG)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Non-transpedicular grafting (NTPG)
Number of subjects: 21
Study: 9777834

Group type: EXPERIMENTAL
Intervention: Desmopressin (1 microg bolus every 2 h when diuresis > 300 mL/h)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Desmopressin
Number of subjects: 97

Group type: COMPARATOR
Intervention: Control
Number of subjects: 97
Study: 7826054

Group type: EXPERIMENTAL
Intervention: Lactovegetarian diet
Number of subjects: 60

Group type: COMPARATOR
Intervention: Regular 1300‐kcal weight‐reducing diet
Number of subjects: 60

Group type: COMPARATOR
Intervention: Lactovegetarian diet and Regular diet
Number of subjects: 60
Study: 3182117

Group type: EXPERIMENTAL
Intervention: Fenticonazole 2% lotion, applied once daily for three weeks
Number of subjects: 46

Group type: COMPARATOR
Intervention: Bifonazole 1% lotion, applied once daily for three weeks
Number of subjects: 46
Study: 29463461

Group type: EXPERIMENTAL
Intervention: Inhaled isopropyl alcohol and 4 mg oral ondansetron
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Inhaled isopropyl alcohol and oral placebo
Number of subjects: 122

Group type: COMPARATOR
Intervention: Inhaled saline solution placebo and 4 mg oral ondansetron
Number of subjects: 122
Study: 27590372

Group type: EXPERIMENTAL
Intervention: Bipolar electrocoagulation hemostasis (Group A)
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Ultrasound scalpel hemostasis (Group B)
Number of subjects: 207

Group type: COMPARATOR
Intervention: Suture technique hemostasis (Group C)
Number of subjects: 207
Study: 24321456

Group type: EXPERIMENTAL
Intervention: Anti-ST information presented alone
Number of subjects: 571

Group type: EXPERIMENTAL
Intervention: Anti-ST information presented with pro-ST information
Number of subjects: 571

Group type: EXPERIMENTAL
Intervention: Anti-smoking information
Number of subjects: 571

Group type: EXPERIMENTAL
Intervention: Product trials
Number of subjects: 571
Study: 23769278

Group type: EXPERIMENTAL
Intervention: PDD-FURS
Number of subjects: 30

Group type: COMPARATOR
Intervention: WL-FURS
Number of subjects: 30

Group type: COMPARATOR
Intervention: CTU
Number of subjects: 30
Study: 20646533

Group type: EXPERIMENTAL
Intervention: GnRH‐a combined with estradiol valerate 0.5 mg and dydrogesteronea 5 mg daily
Number of subjects: 70

Group type: COMPARATOR
Intervention: GnRH‐a
Number of subjects: 70